Montay G, Bruno R, Vergniol J C, Ebmeier M, Le Roux Y, Guimart C, Frydman A, Chassard D, Thebault J J
Institut de Biopharmacie, Rhone Poulenc Rorer, Antony, France.
J Clin Pharmacol. 1994 Nov;34(11):1071-6. doi: 10.1002/j.1552-4604.1994.tb01983.x.
The pharmacokinetics of sparfloxacin at oral doses of 200, 400, 600, and 800 mg were studied in 12 healthy volunteers in a randomized double-blind crossover study. Each dose administration was separated by a 1-week washout period. Plasma and urine samples were collected up to 120 hours postdosing, for determination of free and total (free plus glucurono-conjugated) sparfloxacin levels by high-performance liquid chromatography assay and ultraviolet detection. Mean Cmax values ranged from 705 +/- 158 to 1966 +/- 620 ng/mL for the 200 to 800 mg doses, at median tmax ranging from 4 to 5 hours. A slight decrease of sparfloxacin bioavailability with increasing dose was observed because AUC was 87% to 88% of the expected area when the dose was doubled. The elimination half-life values were constant over the dose range (with values ranging from 18 to 21 hours) as well as the renal clearance. The metabolic ratio conjugated/free drug was not modified by increasing dose.
在一项随机双盲交叉研究中,对12名健康志愿者口服200、400、600和800毫克司帕沙星的药代动力学进行了研究。每次给药间隔1周的洗脱期。给药后长达120小时采集血浆和尿液样本,通过高效液相色谱法和紫外检测测定游离和总(游离加葡萄糖醛酸结合物)司帕沙星水平。200至800毫克剂量的平均Cmax值范围为705±158至1966±620纳克/毫升,中位tmax范围为4至5小时。观察到随着剂量增加司帕沙星的生物利用度略有下降,因为当剂量加倍时AUC为预期面积的87%至88%。消除半衰期值在剂量范围内恒定(值范围为18至21小时),肾清除率也是如此。代谢物与游离药物的比值不会因剂量增加而改变。